Advances in pneumococcal antibiotic resistance

References

• Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr. Opin. Pulm. Med. 16(3), 217–225 (2010).
   PubMed Web of Science ®Google Scholar
• Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin. Microbiol. Infect. 18( Suppl. 5), 7–14 (2012).
   PubMed Web of Science ®Google Scholar
• Hansman D, Bullen MM. A resistant pneumococcus. Lancet 290(7509), 264–265 (1967).
   Google Scholar
• Kislak JW. Type 6 pneumococcus resistant to erythromycin and lincomycin. N. Engl. J. Med. 276(15), 852 (1967).
   PubMedGoogle Scholar
• Piddock LJ, Wise R. The selection and frequency of streptococci with decreased susceptibility to ofloxacin compared with other quinolones. J. Antimicrob. Chemother. 22( Suppl. C), 45–51 (1988).
   PubMedGoogle Scholar
• Jacobs MR, Koornhof HJ, Robins-Browne RM et al. Emergence of multiply resistant pneumococci. N. Engl. J. Med. 299(14), 735–740 (1978).
   PubMed Web of Science ®Google Scholar
• Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365(9459), 579–587 (2005).
   PubMed Web of Science ®Google Scholar
• Chen DK, Mcgeer A, De Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N. Engl. J. Med. 341(4), 233–239 (1999).
   PubMed Web of Science ®Google Scholar
• Lynch JP 3rd, Zhanel GG. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin. Respir. Crit. Care Med. 26(6), 575–616 (2005).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Progress in introduction of pneumococcal conjugate vaccine–worldwide, 2000–2008. Morb. Mortal. Wkly. Rep. 57(42), 1148–1151 (2008).
   PubMedGoogle Scholar
• Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 28(26), 4249–4259 (2010).
   PubMed Web of Science ®Google Scholar
• Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998–2011). Diagn. Microbiol. Infect. Dis. 75(1), 107–109 (2013).
   PubMed Web of Science ®Google Scholar
• Riedel S, Beekmann SE, Heilmann KP et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis. 26(7), 485–490 (2007).
   PubMed Web of Science ®Google Scholar
• Kim SH, Song JH, Chung DR et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob. Agents Chemother. 56(3), 1418–1426 (2012).
   PubMed Web of Science ®Google Scholar
• Song JH, Chang HH, Suh JY et al. Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). J. Antimicrob. Chemother. 53(3), 457–463 (2004).
   PubMed Web of Science ®Google Scholar
• Song JH, Jung SI, Ko KS et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob. Agents Chemother. 48(6), 2101–2107 (2004).
   PubMed Web of Science ®Google Scholar
• Harimaya A, Yokota S, Sato K, Yamazaki N, Himi T, Fujii N. High prevalence of erythromycin resistance and macrolide-resistance genes, mefA and ermB, in Streptococcus pneumoniae isolates from the upper respiratory tracts of children in the Sapporo district, Japan. J. Infect. Chemother. 13(4), 219–223 (2007).
   PubMedGoogle Scholar
• Song JH, Lee NY, Ichiyama S et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin. Infect. Dis. 28(6), 1206–1211 (1999).
   PubMed Web of Science ®Google Scholar
• Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes. Clin. Infect. Dis. 38( Suppl. 4), S322–S327 (2004).
   Google Scholar
• Wierzbowski AK, Swedlo D, Boyd D et al. Molecular epidemiology and prevalence of macrolide efflux genes mef(A) and mef(E) in Streptococcus pneumoniae obtained in Canada from 1997 to 2002. Antimicrob. Agents Chemother. 49(3), 1257–1261 (2005).
   PubMedGoogle Scholar
• Felmingham D, Canton R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001–2004. J. Infect. 55(2), 111–118 (2007).
   PubMed Web of Science ®Google Scholar
• Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg. Infect. Dis. 15(8), 1260–1264 (2009).
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, Klugman KP. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg. Infect. Dis. 11(6), 851–858 (2005).
   PubMedGoogle Scholar
• Wierzbowski AK, Nichol K, Laing N et al. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004). J. Antimicrob. Chemother. 60(4), 733–740 (2007).
   PubMedGoogle Scholar
• Moore MR, Gertz RE Jr., Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197(7), 1016–1027 (2008).
   PubMed Web of Science ®Google Scholar
• Bowers JR, Driebe EM, Nibecker JL et al. Dominance of multidrug resistant CC271 clones in macrolide-resistant Streptococcus pneumoniae in Arizona. BMC Microbiol. 12, 12 (2012).
   PubMedGoogle Scholar
• Ko KS, Song JH. Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains erm(B) and mef(A) genes. J. Infect. Dis. 190(4), 739–747 (2004).
   PubMedGoogle Scholar
• Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. The impact of the pneumococcal conjugate vaccine on antimicrobial resistance in the United States since 1996: evidence for a significant rebound by 2007 in many classes of antibiotics. Microb. Drug Resist. 15(4), 261–268 (2009).
   PubMedGoogle Scholar
• Green K, Mcgeer A, Wong K et al. What will happen to antimicrobial resistance in adult IPD after the introduction of infant PCV13 vaccination in Canada? Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 9–12 September 2012.
   Google Scholar
• Kaplan SL, Barson WJ, Lin PL et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 32(3), 203–207 (2013).
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354(14), 1455–1463 (2006).
   PubMed Web of Science ®Google Scholar
• Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Impact of new Clinical Laboratory Standards Institute Streptococcus pneumoniae penicillin susceptibility testing breakpoints on reported resistance changes over time. Microb. Drug Resist. 17(1), 47–52 (2011).
   PubMedGoogle Scholar
• Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin. Infect. Dis. 48(11), 1596–1600 (2009).
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI Document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2010).
   Google Scholar
• Centers for Disease Control and Prevention. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae – United States, 2006–2007. MMWR Morb. Mortal. Wkly. Rep. 57(50), 1353–1355 (2008).
   PubMedGoogle Scholar
• Su LH, Wu TL, Kuo AJ, Chia JH, Chiu CH. Antimicrobial susceptibility of Streptococcus pneumoniae at a university hospital in Taiwan, 2000–07: impact of modified non-meningeal penicillin breakpoints in CLSI M100-S18. J. Antimicrob. Chemother. 64(2), 336–342 (2009).
   PubMedGoogle Scholar
• Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin. Microbiol. Infect. 16(5), 402–410 (2010).
   PubMed Web of Science ®Google Scholar
• Cornick JE, Bentley SD. Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microbes Infect. 14(7–8), 573–583 (2012).
   PubMedGoogle Scholar
• Nichol KA, Zhanel GG, Hoban DJ. Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46(10), 3261–3264 (2002).
   PubMedGoogle Scholar
• Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol. Rev. 32(2), 361–385 (2008).
   PubMed Web of Science ®Google Scholar
• Chi F, Nolte O, Bergmann C, Ip M, Hakenbeck R. Crossing the barrier: evolution and spread of a major class of mosaic pbp2x in Streptococcus pneumoniae, S. mitis and S. oralis. Int. J. Med. Microbiol. 297(7–8), 503–512 (2007).
   PubMedGoogle Scholar
• Reinert RR, Reinert S, Van Der Linden M, Cil MY, Al-Lahham A, Appelbaum P. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob. Agents Chemother. 49(7), 2903–2913 (2005).
   PubMed Web of Science ®Google Scholar
• Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4. Ann. Clin. Microbiol. Antimicrob. 7, 1 (2008).
   PubMedGoogle Scholar
• Coffey TJ, Dowson CG, Daniels M, Spratt BG. Genetics and molecular biology of beta-lactam-resistant pneumococci. Microb. Drug Resist. 1(1), 29–34 (1995).
   PubMedGoogle Scholar
• Nagai K, Davies TA, Jacobs MR, Appelbaum PC. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob. Agents Chemother. 46(5), 1273–1280 (2002).
   PubMed Web of Science ®Google Scholar
• Maurer P, Todorova K, Sauerbier J, Hakenbeck R. Mutations in Streptococcus pneumoniae penicillin-binding protein 2x: importance of the C-terminal penicillin-binding protein and serine/threonine kinase-associated domains for beta-lactam binding. Microb. Drug Resist. 18(3), 314–321 (2012).
   PubMedGoogle Scholar
• Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin. Infect. Dis. 38( Suppl. 4), S357–S362 (2004).
   PubMedGoogle Scholar
• Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997–2006. Int. J. Antimicrob. Agents 34(1), 82–85 (2009).
   PubMedGoogle Scholar
• Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn. Microbiol. Infect. Dis. 51(1), 31–37 (2005).
   PubMedGoogle Scholar
• Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004–2007). Int. J. Antimicrob. Agents 34(2), 121–130 (2009).
   PubMedGoogle Scholar
• Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob. Agents Chemother. 46(2), 522–524 (2002).
   PubMedGoogle Scholar
• Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40(12), 2760–2764 (1996).
   PubMed Web of Science ®Google Scholar
• Balsalobre L, De La Campa AG. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes. Antimicrob. Agents Chemother. 52(3), 822–830 (2008).
   PubMedGoogle Scholar
• Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 34(4), 482–492 (2002).
   PubMed Web of Science ®Google Scholar
• Jorgensen JH, Mcelmeel ML, Fulcher LC, Mcgee L, Glennen A. Evaluation of disk approximation and single-well broth tests for detection of inducible clindamycin resistance in Streptococcus pneumoniae. J. Clin. Microbiol. 49(9), 3332–3333 (2011).
   PubMedGoogle Scholar
• Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin. Microbiol. Infect. 17( Suppl. 6), E1–E59 (2011).
   Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44( Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Dallas SD, Mcgee L, Limbago B et al. Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae. J. Clin. Microbiol. 51(6), 1798–1802 (2013).
   PubMedGoogle Scholar
• Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 67(16), 2355–2382 (2007).
   PubMed Web of Science ®Google Scholar
• Draghi DC, Jones ME, Sahm DF, Tillotson GS. Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003–2004). Int. J. Antimicrob. Agents 28(6), 525–531 (2006).
   PubMedGoogle Scholar
• Farrell DJ, Couturier C, Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003–2004). Int. J. Antimicrob. Agents 31(3), 245–249 (2008).
   PubMedGoogle Scholar
• Lynch JP, 3rd, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin. Respir. Crit. Care Med. 30(2), 210–238 (2009).
   PubMed Web of Science ®Google Scholar
• Gertz RE Jr., Li Z, Pimenta FC et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J. Infect. Dis. 201(5), 770–775 (2010).
   PubMed Web of Science ®Google Scholar
• Shin J, Baek JY, Kim SH, Song JH, Ko KS. Predominance of ST320 among Streptococcus pneumoniae serotype 19A isolates from 10 Asian countries. J. Antimicrob. Chemother. 66(5), 1001–1004 (2011).
   PubMedGoogle Scholar
• Beall BW, Gertz RE, Hulkower RL, Whitney CG, Moore MR, Brueggemann AB. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J. Infect. Dis. 203(10), 1360–1368 (2011).
   PubMed Web of Science ®Google Scholar
• Hulten KG, Kaplan SL, Lamberth LB et al. Changes in Streptococcus pneumoniae serotype 19A invasive infections in children from 1993 to 2011. J. Clin. Microbiol. 51(4), 1294–1297 (2013).
   PubMedGoogle Scholar
• Vestrheim DF, Steinbakk M, Aaberge IS, Caugant DA. Postvaccination increase in serotype 19A pneumococcal disease in Norway is driven by expansion of penicillin-susceptible strains of the ST199 complex. Clin. Vaccine Immunol. 19(3), 443–445 (2012).
   PubMedGoogle Scholar
• Green K, Mcgeer A, Wong K et al. Surveillance for antimicrobial resistance in Streptococcus pneumoniae in Canada, 1993–2011. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 9–12 September 2012.
   Google Scholar
• Kang CI, Baek JY, Jeon K et al. Bacteremic pneumonia caused by extensively drug-resistant Streptococcus pneumoniae. J. Clin. Microbiol. 50(12), 4175–4177 (2012).
   PubMedGoogle Scholar
• Ko KS, Baek JY, Song JH. Multidrug-resistant Streptococcus pneumoniae serotype 6D clones in South Korea. J. Clin. Microbiol. 50(3), 818–822 (2012).
   PubMedGoogle Scholar
• Niederman MS, Luna CM. Community-acquired pneumonia guidelines: a global perspective. Semin. Respir. Crit. Care Med. 33(3), 298–310 (2012).
   PubMed Web of Science ®Google Scholar